What is the protocol for managing status epilepticus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Status Epilepticus Management Protocol

Status epilepticus should be treated immediately with IV lorazepam 0.05 mg/kg (maximum 4 mg) given slowly (2 mg/min) as first-line therapy, followed by additional antiseizure medications if seizures persist after 10-15 minutes. 1, 2

Definition and Initial Assessment

  • Status epilepticus: Continuous seizure lasting >5 minutes or multiple seizures without return to baseline consciousness
  • Immediate priorities:
    • Ensure patent airway and adequate ventilation
    • Establish IV access
    • Monitor vital signs
    • Obtain blood for laboratory studies (glucose, electrolytes, toxicology)

Treatment Algorithm

First-Line Treatment (0-10 minutes)

  • Lorazepam 0.05 mg/kg IV (maximum 4 mg) administered at 2 mg/min 2
  • Success rate: approximately 65% 1
  • Key adverse effect: respiratory depression
  • If IV access is unavailable, consider midazolam 0.2 mg/kg IM (maximum 6 mg) 1

Second-Line Treatment (10-30 minutes)

If seizures continue or recur after 10-15 minutes:

  • Additional lorazepam 4 mg IV may be administered 2
  • PLUS one of the following:
    • Fosphenytoin/Phenytoin: 18-20 mg/kg IV (success rate: 56%) 1
    • Valproate: 20-30 mg/kg IV (success rate: 88%) 1
    • Levetiracetam: 30-50 mg/kg IV (success rate: 44-73%) 1

Third-Line Treatment (Refractory Status Epilepticus, >30 minutes)

If seizures persist despite first and second-line treatments:

  • Phenobarbital: 10-20 mg/kg IV (success rate: 58%) 1
  • If still refractory, consider general anesthesia with:
    • Propofol
    • Midazolam
    • Pentobarbital/thiopental

Maintenance Therapy

After seizure control is achieved:

  • Lorazepam: 0.05 mg/kg (maximum 1 mg) IV every 8 hours for 3 doses 1
  • Levetiracetam: 15 mg/kg (maximum 1,500 mg) IV every 12 hours 1
  • Phenobarbital: 1-3 mg/kg IV every 12 hours (if used) 1

Monitoring Requirements

  • Continuous cardiorespiratory monitoring (77% risk of hypotension) 1
  • Frequent neurological assessments
  • EEG monitoring for high-risk populations or if patient requires neuromuscular blockade
  • Laboratory monitoring: baseline renal and hepatic function, periodic electrolytes, drug levels when appropriate 1

Special Considerations

  • Equipment for airway management must be immediately available before administering benzodiazepines 2
  • Status epilepticus may result from correctable causes (hypoglycemia, hyponatremia, toxic/metabolic derangements) that must be identified and treated 2
  • Consider neurology consultation if patient fails to respond to initial treatment 2
  • Non-convulsive status epilepticus should be considered in patients who don't regain consciousness after convulsive seizures stop 1

Common Pitfalls and Caveats

  • Delaying treatment beyond 5-7 minutes increases risk of neurological damage 3
  • Underdosing first-line medications (particularly benzodiazepines)
  • Failing to prepare for respiratory depression when administering benzodiazepines
  • Not considering non-convulsive status epilepticus in patients who remain unresponsive
  • Failing to identify and treat underlying causes
  • Subtle status epilepticus (coma with ictal EEG discharges) has lower treatment success rates (7.7-24.2%) compared to overt status epilepticus 4

The protocol outlined above represents the most current evidence-based approach to managing status epilepticus, with lorazepam showing superiority as first-line treatment compared to phenytoin alone 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.